[Hodgkin Lymphoma].
Hodgkin lymphoma affect about 1500 new patients annually in France and 60% of the patients presented a localized disease. HL is highly curable with chemotherapy such as ABVD and escalated BEACOPP and for limited stage, consolidation with involved-field or involved nodes radiation therapy. Treatment could be optimized using positron emission tomography (PET) scan performed after 2 cycles to identify early responders and PET2 positive patients who are at high risk of relapse. Hodgkin lymphoma is characterized a minority of malignant Hodgkin and Reed-Sternberg (HRS) cells and a predominance of inflammatory cells. HRS cells could be targeted by antibody drug conjugates targeting CD30 showing a strong efficacy for relapsed patients. Monoclonal antibodies that are directed against the immune checkpoints especially the PD-1- PD-L1/L2 axis showed also a significant activity for patients relapsing after brentuximab vedotin and autograft. These targeted drugs are currently testing in clinical trials in early phase of the disease.